NorthStrive Biosciences Reports Preliminary EL-32 Combination Study Findings
The preclinical study with semaglutide identified a preliminary lean-mass finding at the highest EL-32 dose. The results are informing the next phase of development.
The preclinical study with semaglutide identified a preliminary lean-mass finding at the highest EL-32 dose. The results are informing the next phase of development.